Reversible protein serine/threonine phosphorylation in higher eukaryotes is catalyzed by protein kinases and phosphatases (1). The functional diversity of protein phosphatases is increased by the presence of isoforms of the catalytic subunits and numerous noncatalytic or regulatory subunits. For example, there are four mammalian isoforms of the catalytic subunit of type-1 protein phosphatases (2, 3). These catalytic subunits (PP-1 C ) 1 are anchored at various subcellular locations by their association with targeting subunits that also define the substrate specificity and activity of the enzyme. Of the nearly 20 PP-1-targeting subunits thus far identified in mammalian cells, the best characterized is the G subunit which targets PP-1 C to glycogen and enhances its glycogen-synthase phosphatase activity (4 -6). Interaction of the skeletal muscle G M subunit with PP-1 C is in part mediated by an RVXF motif that binds in an extended conformation within a hydrophobic channel near the C terminus of PP-1 C (5, 6). Phosphorylation of G M by protein kinase A (PKA) at a threonine in the X position abolished PP-1 binding. Variants of the RVXF motif are present in many other PP-1 regulators, including the myosin-binding or M subunit, the p53 binding-protein-2, inhibitor-1, DARPP-32, and inhibitor-2 (5-10). Moreover, the regulation of PP-1 C by these proteins was impaired by mutations within the RVXF motif or by the presence of competing RVXF-containing peptides. However, these regulators also possessed other interaction sites with PP-1 C in addition to the RVXF motif (4, 5, 8) . Biochemical (11) and immunofluorescence (12) studies showed that a large fraction of PP-1 is present in the nucleus. Nuclear PP-1 (PP-1N) has been implicated in the regulation of mRNA splicing (13), in the cell cycle-dependent control of the retinoblastoma protein (14) and lamin B (15), and in the dephosphorylation of the transcription factors CREB (16) and Sp1 (17). However, the PP-1 holoenzymes involved and their regulation remain poorly understood.
Reversible protein serine/threonine phosphorylation in higher eukaryotes is catalyzed by protein kinases and phosphatases (1) . The functional diversity of protein phosphatases is increased by the presence of isoforms of the catalytic subunits and numerous noncatalytic or regulatory subunits. For example, there are four mammalian isoforms of the catalytic subunit of type-1 protein phosphatases (2, 3) . These catalytic subunits (PP-1 C ) 1 are anchored at various subcellular locations by their association with targeting subunits that also define the substrate specificity and activity of the enzyme. Of the nearly 20 PP-1-targeting subunits thus far identified in mammalian cells, the best characterized is the G subunit which targets PP-1 C to glycogen and enhances its glycogen-synthase phosphatase activity (4 -6) . Interaction of the skeletal muscle G M subunit with PP-1 C is in part mediated by an RVXF motif that binds in an extended conformation within a hydrophobic channel near the C terminus of PP-1 C (5, 6) . Phosphorylation of G M by protein kinase A (PKA) at a threonine in the X position abolished PP-1 binding. Variants of the RVXF motif are present in many other PP-1 regulators, including the myosin-binding or M subunit, the p53 binding-protein-2, inhibitor-1, DARPP-32, and inhibitor-2 (5-10). Moreover, the regulation of PP-1 C by these proteins was impaired by mutations within the RVXF motif or by the presence of competing RVXF-containing peptides. However, these regulators also possessed other interaction sites with PP-1 C in addition to the RVXF motif (4, 5, 8) . Biochemical (11) and immunofluorescence (12) studies showed that a large fraction of PP-1 is present in the nucleus. Nuclear PP-1 (PP-1N) has been implicated in the regulation of mRNA splicing (13) , in the cell cycle-dependent control of the retinoblastoma protein (14) and lamin B (15) , and in the dephosphorylation of the transcription factors CREB (16) and Sp1 (17) . However, the PP-1 holoenzymes involved and their regulation remain poorly understood. The two major nuclear targeting subunits of PP-1 have been identified (11) as NIPP-1 and R111, which is also known as p99 (18) or PNUTS (19) . NIPP-1 and R111 are each associated with 30 -50% of PP-1 C in mammalian nuclei and may target PP-1 to RNA (19 -21) . NIPP-1 potently inhibits PP-1 C activity in vitro (K i ϭ 1-10 pM), and the NIPP-1⅐PP-1 C complex (PP-1N NIPP-1 ) is essentially inactive. However, PP-1N NIPP-1 can be reactivated by phosphorylation with PKA and protein kinase CK2, without disruption of the holoenzyme (21) . Two phosphorylation sites, Ser 199 for PKA and Ser 204 for CK2, flank an RVXF motif that may contribute to PP-1 binding. Thus, the phosphorylation of NIPP-1 may impair or disrupt the interaction of PP-1 with the RVXF motif and thereby enhance nuclear PP-1 activity. On the other hand, there must be yet other interactions between PP-1 and NIPP-1 that maintain the association of these two proteins in the active complex. It is also highly unlikely that the RVXF motif itself mediates PP-1 inhibition, because this sequence is present in many PP-1 regulators that do not inhibit enzyme activity. Thus, the precise molecular basis for PP-1 inhibition by NIPP-1 remains unknown.
In the studies described, we have analyzed the association of NIPP-1 and PP-1 C by the yeast two-hybrid assay as well as by co-sedimentation. Further studies used numerous synthetic peptides based on NIPP-1 to identify two sequences in the central domain that independently mediate PP-1 binding and inhibition. A synthetic peptide encompassing these two sequences effectively competed for PP-1 inhibition by full-length NIPP-1 as well as other PP-1 inhibitors. Our studies established that phosphorylation of the synthetic NIPP-1 peptide on the two serines flanking the RVXF motif resulted in the dissociation of this motif from PP-1 C and decreased the potency of the peptide as a PP-1 inhibitor. Other experiments suggested that sequences outside the central domain were also required for the continued and stable association of PP-1 C with fulllength NIPP-1 following its phosphorylation and inactivation by PKA and CK2. Together, these studies provided the first insights into the molecular determinants for the regulation of nuclear PP-1 by NIPP-1.
EXPERIMENTAL PROCEDURES
Materials-PP-1 C (22) and phosphorylase b (23) were purified from rabbit skeletal muscle. Digoxygenin-labeled PP-1 C was prepared according to Beullens et al. (24) using the digoxygenin protein labeling kit purchased from Roche Molecular Biochemicals. CNBr-activated Sepharose, glutathione-Sepharose, and Blue Sepharose were purchased from Amersham Pharmacia Biotech. Peptides were synthesized on Milligen 9050, using the N-(9-fluorenyl)methoxycarbonyl method. For the PP-1-binding assays, the synthetic peptides were coupled to bovine serum albumin using glutaraldehyde (25) . Phosphorylase b was phosphorylated in the presence of [␥-32 P]ATP by purified phosphorylase kinase (26) .
Preparation of Recombinant Proteins-Bovine NIPP-1 was expressed in Sf9 cells using the baculovirus system and purified according to Vulsteke et al. (21) . Oligonucleotides 5Ј-ATCGAACATATGGGTG-GAGAGGATGATGAAC-3Ј (NdeI site underlined) and 5Ј-CTGCACG-GATCCTCAGTTCCGAAAGCGACCAACC-3Ј (BamHI site underlined) were used as sense and antisense primers in a PCR reaction using the NIPP-1 cDNA as template to yield a product encoding NIPP-1 143-217 , which was verified by double-stranded sequencing. The PCR product was digested with NdeI/BamHI and subcloned into pET-16b (Novagen) for expression in bacteria as a polyhistidine-tagged protein. Escherichia coli BL21(DE3) cells, transformed with the expression vector, were grown at 37°C in LB medium supplemented with 200 g/ml ampicillin, to reach an A 600 of 0.6 -0.8. NIPP-1 protein was induced by the addition of 1 mM isopropyl-1-thio-␤-D-galactopyranoside. After 2 h at 30°C, bacteria were collected by centrifugation (10 min at 5,000 ϫ g) and resuspended in lysis buffer (pH 7.9) containing 20 mM Tris/HCl, 5 mM imidazole, 0.5 M NaCl, 0.5 mM phenylmethanesulfonyl fluoride, 0.5 mM benzamidine, and 5 M leupeptin. Cells were disrupted by three cycles of freezing in liquid N 2 , followed by boiling for 15 min. After centrifugation for 20 min at 20,000 ϫ g, the supernatant was applied to a 5-ml Ni 2ϩ -IDA-Sepharose column (Sigma) equilibrated in lysis buffer. The column was washed with 25 ml of lysis buffer containing in addition 100 mM imidazole, and the protein was eluted with 50 ml of lysis buffer containing 400 mM imidazole. Fractions containing NIPP-1 143-217 were pooled, concentrated in a Vivaspin ultrafiltration unit (VivaScience), and dialyzed against 20 mM Tris/HCl at pH 7.5.
Human inhibitor-1 was expressed in E. coli as a fusion protein with glutathione S-transferase and purified on glutathione-Sepharose as described by Endo et al. (27) . Glutathione S-transferase inhibitor-1 was digested with thrombin (1 units/ml for 60 min) and boiled for 5 min, and inhibitor-1 was separated from the denatured proteins by centrifugation (5 min at 10,000 ϫ g). Purified inhibitor-1 was phosphorylated with PKA catalytic subunit (27) . Inhibitor-2 was purified from heat-treated lysates from BL21(DE3) cells transformed with pET8d inhibitor-2 plasmid (kindly provided by Prof. A. A. DePaoli-Roach) using chromatography on Blue Sepharose (28) .
Coupling of Inhibitor-1 and NIPP-1 to Sepharose-NIPP-1 , NIPP-1 , and phosphorylated inhibitor-1 (80 g of protein) were each coupled to 0.5 ml of CNBr-activated Sepharose as described by the manufacturer. The gels were incubated with 10 pmol of PP-1 C for 30 min at 4°C on a rotating wheel. The unbound PP-1 C was removed by washing with buffer A (50 mM glycylglycine, pH 7.4, containing 0.5 mM dithiothreitol and 5 mM ␤-mercapthoethanol). The matrices were incubated with an equal volume of buffer A containing 150 mM NaCl and 10 M NIPP-1
191-210 for 10 min at 25°C. Following centrifugation (5 min at 15,000 ϫ g), the gel was washed twice with buffer A containing 150 mM NaCl and resuspended in the same buffer. The pellet and supernatant were assayed for phosphorylase phosphatase activity before and after incubation with trypsin as described (29) . One unit of phosphatase releases 1 nmol of phosphate/min at 30°C.
Assays-NIPP-1, its fragments, inhibitor-1, and inhibitor-2 were assayed as inhibitors of the phosphorylase phosphatase activity of PP-1 C (29) . The inhibitor-2-mediated inactivation of PP-1 C was monitored by the time-dependent decrease in trypsin-revealed phosphorylase phosphatase activity (2) . The inhibitors were diluted in buffer A containing bovine serum albumin (1 mg/ml) and 0.05% Triton X-100. All phosphatase assays were carried out in buffer A, except for the inhibitor-2-induced inactivation, which was undertaken in 50 mM imidazole, pH 7.4, containing 0.5 mM dithiothreitol, 5 mM ␤-mercapthoethanol, and 1 mg/ml bovine serum albumin. Phosphatase assays at pH 5.0 and 6.0 were carried out in buffer containing 20 mM Tris, 20 mM MES, 20 mM CAPS, and 0.1% of Triton X-100, adjusted to the desired pH at room temperature.
For the far-Western with digoxygenin-labeled PP-1 C , the albumincoupled peptides were slot-blotted on polyvinylidene difluoride membrane (Bio-Rad), and the bound PP-1 was visualized using anti-digoxygenin antibodies (24) . Protein concentrations were measured according to Bradford (30) with bovine serum albumin as standard. Statistics are given as the means Ϯ S.E. for the indicated number (n) of experiments.
Yeast Two-hybrid Assays-The plasmid pAS1-Glc7 (31) encodes the yeast PP-1 catalytic subunit fused to the Gal4 DNA-binding domain (residues 1-147). The cDNAs encoding full-length NIPP-1 (351 residues) and various fragments (NIPP-1 (32) , in-frame with the Gal4 activation domain (residues 768 -881) and the hemagglutinin (HA) epitope. Full-length NIPP-1 cDNA was cloned into the pACT2 vector in two steps. First, PCR was carried out using pBl-2175 as template (33) and 5Ј-ATCGA-ACCGCGGCCATGGAGGCCATGGCGGCAGCCGCGAACTC-3Ј (the SacII site is shown in bold and the SfiI site is underlined) and 5Ј-AG-AAAGTGCCGTGTGTAC-3Ј as primers. The PCR product (300 base pairs) was digested with SacII and ClaI, and the resulting 118-base pair fragment was exchanged for the SacII-ClaI fragment of the original pBl-2175 vector. The second step involved digestion of this vector with SfiI and XhoI, which excised the entire NIPP-1 cDNA, which was then cloned into the SfiI-XhoI sites of the pACT2 vector. In the yeast two-hybrid assay, Saccharomyces cerevisiae strains Y190 and Y187 were transformed by the lithium acetate method of Gietz et al. (34) with pACT2-NIPP-1-fragments and pAS1-Glc7, respectively. Individual transformants were purified on selection media (synthetic complete medium lacking leucine for Y190 or tryptophan for Y187) and grown at 30°C. After mating of the appropriate yeast transformants, diploids were selected on a medium deficient in both Trp and Leu. Expression of ␤-galactosidase was determined in duplicate after 8 h, using the 5-bromo-4-chloro-3-indolyl ␤-D-galactopyranoside filter assay described in the CLONTECH Yeast Protocols Handbook.
Co-sedimentation of NIPP-1 and PP-1 C -Overnight cultures (20 ml) of Y190 yeast transformed with pACT2-NIPP-1 constructs were inoculated into 200 ml of synthetic complete medium minus leucine. Cells were grown to an A 600 of 0.5-0.8, harvested by centrifugation, washed with water, and resuspended in 500 l of buffer B, containing 50 mM Tris/HCl, pH 7.5, 0. Tris/HCl, pH 7.5, 150 mM NaCl) and twice with TBS and resuspended in 225 l of buffer C containing 10 mM Tris/HCl, pH 7.5, 0.1 M NaCl, 0.05% Triton, 1 mM dithiothreitol, and the mixture of protease inhibitors present in buffer B. Aliquots (50 l) of the immunoprecipitates were incubated for 10 min with either buffer or with 1 pmol PP-1 C on a rotating wheel, washed twice with buffer C, resuspended in 45 l buffer C, and assayed for spontaneous and trypsin-activated phosphorylase phosphatase activity. The phosphatase activities (derived from endogenous Glc7p and added muscle PP-1 C ) were normalized for the amount of NIPP-1 fusion proteins in the immunoprecipitates, as determined by Western blotting with antibodies against the Gal4 activation domain (CLONTECH).
RESULTS AND DISCUSSION
Identification of PP-1 Binding Sites-Initial studies of NIPP-1 interactions with PP-1 C were undertaken using the yeast two-hybrid assay. For this purpose, the cDNAs encoding bovine NIPP-1 and various fragments were subcloned in the pACT2 vector containing the Gal4 transcriptional activation domain fused at its C terminus to a HA tag (Fig. 1A) . The cDNA encoding the budding yeast PP-1 catalytic subunit (Glc7p) was subcloned in the pAS vector containing the Gal4 DNA-binding domain. Additional experiments showed that purified Glc7p was inhibited by bovine NIPP-1 with similar potency to mammalian PP-1 catalytic subunit (data not shown). Mating single transformants containing pAS-Glc7 with those containing pACT2-NIPP-1 yielded double tranformants that contained the ␤-galactosidase reporter gene under the control of the Gal4 promoter. Analysis of numerous NIPP-1 constructs (Fig. 1B) showed that only strains that expressed both Glc7p and NIPP-1 fragments containing residues 167-224 were stained blue with 5-bromo-4-chloro-3-indolyl ␤-D-galactopyranoside (Fig. 1B) .
In additional experiments, we used the monoclonal anti-HA antibodies to immunoprecipitate Gal4-NIPP-1 fusion proteins from extracts of single-transformed yeast. Subsequently, it was investigated whether endogenous Glc7p had co-sedimented with the fusion proteins and whether additional catalytic subunit could be bound by the immunoprecipitates, when preincubated with an excess of PP-1 C from rabbit skeletal muscle. The "spontaneous" phosphatase activity in these immunoprecipitates was assayed using phosphorylase a as substrate. Because the complex of intact NIPP-1 and PP-1 C is inactive (21), we also assayed for "total" PP-1 activity following the trypsin digestion of NIPP-1 present in the immunoprecipitates. Because PP-1 C is fully active after trypsinization, the total activity can be taken as a measure of the amount of catalytic subunit. Thus, the assay of spontaneous and total activity enabled us to differentiate between fragments of NIPP-1 that bound PP-1 C and those that also inhibited enzyme activity (2). In comparison with the endogenous Glc7p activity that was co-immunoprecipitated, four to seven times more phosphorylase phosphatase activity co-sedimented with the NIPP-1 fusion proteins when the immunoprecipitates were preincubated with an excess of muscle PP-1 C (Fig. 1C) . This suggests that the immunoprecipitated NIPP-1 fusion proteins were only partially saturated with endogenous Glc7p, either because the level of Glc7p was limiting or because Glc7p was dissociated during the washing of the immunoprecipitates with 0.25 M LiCl. Fig. 1C compares the binding and inhibition of endogenous Glc7p or Glc7p plus muscle PP-1 C by equivalent molar amounts of NIPP-1 fusion proteins, as measured by Western analysis with anti-Gal4 antibodies. Compared with full-length NIPP-1 , the immunoprecipitates with the Gal4 fusions containing either the N terminus, NIPP-1 or the C terminus, NIPP-1 , showed no significant PP-1 C binding as assessed after trypsin digestion. On the other hand, the Gal4-NIPP-1 143-224 fusion protein bound PP-1 C and effectively inhibited its activity. Interestingly, a further Nterminal deletion to produce NIPP-1 167-224 yielded a higher spontaneous PP-1 activity in the immunoprecipitates than obtained A series of overlapping 20-mer peptides encompassing the entire central domain were tested for their ability to inhibit PP-1 C purified from rabbit skeletal muscle. IC 50 is the concentration of peptide (means Ϯ S.E., n ϭ 4) that inhibited the phosphorylase phosphatase activity of PP-1 C by 50%. Also shown is the ability of albumin-coupled peptides to bind digoxygenin-labeled PP-1 C (DIG-PP-1 C ) in a far-Western assay.
TABLE I Determinants of PP-1 C inhibition by NIPP-1 191-200
IC 50 refers to the peptide concentration required for 50% inhibition of PP-1 C (means Ϯ S.E. for four assays). The first line shows unmodified NIPP-1 [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] . In the other peptides the substituted residues are underlined. . Moreover, this activity was further increased by only 2-fold following trypsin treatment. This suggested that residues 143-167, albeit not inhibitory by themselves (Fig. 1C) , were also required for effective PP-1 inhibition. Essentially the same results were obtained for the binding and inhibition of Glc7p or muscle PP-1 C by these NIPP-1 fusion proteins (Fig. 1C) , suggesting that similar structural determinants mediate the interactions of NIPP-1 with the mammalian and yeast catalytic subunits.
To more precisely delineate the PP-1 binding sites in NIPP-1, we synthesized a series of overlapping 20-mer peptides that together encompassed the central domain of NIPP-1 defined by the sequence (residues 141-230). Of the eight peptides analyzed, only two, NIPP-1 181-200 and NIPP-1 [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] , inhibited PP-1 C , with IC 50 values of 32 and 11 M, respectively (Fig. 2) . A decapeptide representing the overlapping sequence, NIPP-1 [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] , was then synthesized and shown to inhibit PP-1 activity with an IC 50 of 8 M (Table I) . This peptide lacked an RVXF consensus sequence and thus clearly established that enzyme inhibition was not mediated by this motif. Substitution of pairs of adjacent basic residues with Ala increased the IC 50 of the decapeptide by 2-3-fold (Table I) . On the other hand, substitution of the three Lys residues for Arg did not significantly alter the inhibitory potency of the decapeptide. Collectively, these data suggested that the overall basic nature of the peptide, rather than other features, such as the occurrence of alternating Lys and Arg residues, mediates PP-1 C inhibition.
We also investigated the direct association of the synthetic peptides with PP-1 C using a far-Western assay. The synthetic peptides directly immobilized on polyvinylidene difluoride membranes failed to bind the digoxygenin-conjugated PP-1 C (data not shown). However, when first coupled to albumin, the peptide NIPP-1 191-210 readily bound PP-1 C (Fig. 2) . Surprisingly, NIPP-1 [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] , already shown to inhibit PP-1 C activity, failed to bind PP-1 C in the far-Western assay. This suggested that the inhibitory site (residues 191-200) was not recognized in this assay and that the digoxygenin-conjugated PP-1 C preferentially associated with the region of NIPP-1 containing the RVXF motif. Support for this hypothesis comes from the observation that the majority of PP-1-binding proteins that can be visualized by far-Western analysis contain this highly conserved PP-1-binding motif. To check whether the binding of NIPP-1 [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] to PP-1 C in the far-Western assay was indeed mediated via the RVXF motif (residues 200 -203), we analyzed NIPP-1
191-210 peptides containing the substitutions V201A and/or F203A (Fig. 3B) . These studies showed that like NIPP- (Fig. 3A) , further emphasizing that the RVXF motif did not mediate PP-1 inhibition. These data also showed that the farWestern assay visualized the interaction of NIPP-1 with PP-1 C via the RVXF motif but could not be used as an indicator for the binding to PP-1 C via other NIPP1 site(s).
The above data identified at least two distinct interactions of PP-1 C with the central domain, NIPP-1 , that inhibited PP-1 C with essentially identical potency to full-length NIPP-1 (IC 50 ϭ 0.3 nM). However, the synthetic peptide NIPP-1 191-210 , which retained these two PP-1 binding sites, was a much weaker inhibitor of PP-1 (IC 50 ϭ 11 M). This could point to the existence of additional interaction sites in the central domain that could not be identified by two-hybrid analysis, far-Westerns, and phosphatase inhibition assays. Alternately, the reduced potency of the NIPP-1 191-210 peptide may arise from the inability of the PP-1 regulatory sequences to assume the conformation found in NIPP-1 . In this regard, it is interesting to note that the deletion of residues 143-166, which did not directly mediate PP-1 binding, also increased the spontaneous activity of the PP-1 C ⅐NIPP-1 167-224 complex (Fig. 1C) . Competition between NIPP-1 [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] and Endogenous PP-1 Inhibitors-The inactive complex of NIPP-1 and PP-1 C , previously shown to be reactivated by phosphorylation with PKA and/or CK2 (21), was also activated by the addition of NIPP-1 [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] (Fig. 4A) . This "deinhibition" effect was observed at peptide concentrations that were themselves only marginally inhibitory, indicating effective competition for PP-1 binding between NIPP-1 and the less potent NIPP-1 191-210 peptide that alleviated PP-1 inhibition.
The deinhibition of PP-1N NIPP-1 by NIPP-1 191-210 was, however, only seen at physiological salt concentration, i.e. 150 mM NaCl (data not shown). A similar salt requirement was previously noted for the activation of PP-1N NIPP-1 by PKA and CK2 (21) . On the other hand, 150 mM NaCl was not required for the activation of a complex formed with PP-1 C and the central domain, NIPP-1 143-217 , by either phosphorylation or addition of the NIPP-1
191-210 competitor (data not shown). This indicated that despite their similar inhibitory potency, the central domain forms a less stable complex with PP-1 C than does full- (n ϭ 3) . B shows the ability of the same peptides coupled to albumin to bind digoxigenin-labeled PP-1 C (DIG-PP-1 C ) in the far-Western assay.
length NIPP-1. Our data also suggested that in the absence of salt, there are additional phosphatase binding site(s) in the Nand/or the C-terminal domains of NIPP-1.
Because the RVXF motif did not mediate PP-1 inhibition but was a determinant of PP-1 C interaction with NIPP-1 191-210 , this raised the question of whether the NIPP-1 peptide also competed with other PP-1 inhibitors that contained a RVXF motif. Thus, we examined the competition between NIPP-1 191-210 and two other PP-1 inhibitors, inhibitor-1 and inhibitor-2, which contain variants of the consensus RVXF motif (8, 10) . Inhibitor-2 also mediates a time-dependent inactivation of PP-1 C that can be readily distinguished from enzyme inhibition by the inability to recover total enzyme activity following the proteolytic degradation of inhibitor-2 (2). Our data showed that PP-1 inhibition by inhibitor-1 and inhibitor-2 as well as the inhibitor-2-mediated inactivation of PP-1 C were reversed by NIPP-1 [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] (Fig. 4, B and C) , suggesting potential competition between these inhibitors at the RVXF-binding site. This hypothesis was strengthened by the finding that mutant NIPP-1
191-210 peptides with the substitutions V201A Functional Effects of NIPP-1 [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] Phosphorylation-Our previous studies had shown that the potency of NIPP-1 as a PP-1 inhibitor was reduced by its phosphorylation by PKA and/or CK2 and had established the phosphorylation sites for PKA (Ser 199 ) and CK2 (Ser 204 ) that flanked the RVXF motif (21) . In the present study, we investigated the functional impact of these phosphorylations on the NIPP-1 191-210 peptide. Synthesis of NIPP-1 [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] with phosphoserine at either position 199 or 204 significantly reduced its activity as a PP-1 inhibitor (Fig. 6A) . The doubly phosphorylated peptide showed an even greater reduction in its PP-1 inhibitory activity. We have also found that phosphoserine-199 and/or phosphoserine-204 abolished PP-1 C binding to NIPP-1 191-210 in far-Western assays (Fig. 6B) . Likewise, the phosphorylated NIPP-1 [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] was less efficient in competing for inhibition of PP-1 C by inhibitor-1 and -2 (data not shown) and in reversing the inhibitor-2-mediated inactivation of PP-1 C (Fig. 7) .
The above data suggested that phosphorylation of the flanking serines impaired PP-1 binding at or near the RVXF motif and reduced the activity of NIPP-1
191-210 as a PP-1 inhibitor. We speculate that the reduced inhibitory potency of phospho- rylated NIPP-1 191-210 is accounted for by an electrostatic interaction of the phosphate groups with basic residues in the upstream inhibitory binding site, which we have shown to be positive determinants of the inhibitory potency (Table I) . This would also explain why the substitutions V201A or F203A, albeit causing a disruption of the RVXF motif, did not affect the potency of NIPP-1
191-210 as a PP-1 inhibitor (Fig. 3) . Conclusions-The present study identified two interactions of PP-1 C with the central domain of NIPP-1. One, mediated by the consensus RVXF motif found in many other PP-1 C -binding proteins, did not inhibit enzyme activity. The second interaction occurred through a highly basic sequence immediately N-terminal to the RVXF motif and inhibited enzyme activity. However, a peptide encompassing both sequences (NIPP-1 191-210) did not inhibit PP-1 activity at subnanomolar concentrations as seen with NIPP-1 . This implied that other sequences within the central domain were also required to enhance the potency of NIPP-1 as a PP-1 inhibitor. Because no additional inhibitory fragments could be detected in the central domain in our experiments (Fig. 2) , we have postulated that NIPP-1 143-217 is a more potent inhibitor because of its unique conformation.
NIPP-1 191-210 also harbored the determinants for NIPP-1 regulation by PKA and CK2. Our data showed that the phosphorylation of two serines in NIPP-1 191-210 decreased its affinity for PP-1 and concomitantly reduced its activity, both as a direct PP-1 inhibitor and as a competitor with other PP-1 inhibitors. Finally, we have provided evidence suggesting that the N-terminal and/or C-terminal thirds of NIPP-1 are required for its stable association with PP-1 C following phosphorylation by PKA and CK2.
The crystal structure of a complex between PP-1 C and a synthetic fragment of the muscle G M subunit has revealed that the RVXF motif binds in a hydrophobic channel within the C-terminal region of PP-1 C , which is located some distance from the catalytic-site channel (5, 6) . The inhibitory sequence (residues 191-200) in the central domain of NIPP-1 would appear to be too close to the RVXF motif to bridge the distance between the hydrophobic channel and the catalytic site. We therefore propose that the inhibition of PP-1 C by NIPP-1 does not result from its direct interaction with the catalytic site but rather results from interactions of the basic inhibitory NIPP-1 site (residues 191-200) with acidic residues immediately adjacent to the RVXF-binding site in PP-1 C . This mechanism would be different from that proposed for the inhibition of PP-1 C by the cytoplasmic proteins, inhibitor-1, and DARPP-32, which only become potent PP-1 inhibitors after their phosphorylation by PKA (5, 8, 9) . It is worth noting that two PP-1 binding sites have also been mapped within the N-terminal 30 residues of inhibitor-1 and DARPP-32. One of these is the KIQF sequence, similar to RVXF in other PP-1 regulators, which probably binds in the same hydrophobic groove in the PP-1 catalytic subunit. The second interaction most likely occurs through the PKAphosphorylated threonine, which associates with the PP-1 catalytic site and functions as a pseudosubstrate to inhibit enzyme activity. Hence, multiple interactions between PP-1 C and its endogenous inhibitors may be a recurrent mechanism for PP-1 regulation.
In summary, we have defined a complex interaction of PP-1 C with a major nuclear regulatory subunit, NIPP-1, and identified a unique polybasic sequence in NIPP-1 that is essential for PP-1 inhibition. We have also gained better insight into the phosphorylation mechanism that activates the nuclear phosphatase PP-1N NIPP-1 . Although the present studies hint at the existence of additional regulatory sequences in NIPP-1 that greatly enhance its activity as a PP-1 inhibitor, it raises the intriguing possibility that mutations can be introduced into the PP-1 catalytic subunit that will selectively impair its regulation by NIPP-1. Thus, these structure-function studies open the way for addressing the physiological role of NIPP-1 in the control of nuclear PP-1 activity.
